Eli Lilly And Company (LLY)
NYSE:LLY
Want to see LLY full AI Analyst Report?
LLY Stock Chart & Stats
$927.03
$13.01(1.27%)
At close: 4:00 PM EST
$927.03
$13.01(1.27%)
Day’s Range― - ―
52-Week Range$623.78 - $1,182.73
Previous Close$1,036.53
Volume3.30M
Average Volume (3M)3.28M
Market Cap
$1.06T
Enterprise Value$1.09T
Total Cash (Recent Filing)$5.28B
Total Debt (Recent Filing)$43.37B
Price to Earnings (P/E)39.7
Beta0.66
Next Earnings
Aug 05, 2026EPS Estimate
8.81Next Dividend Ex-DateN/A
Dividend Yield0.58%
Share Statistics
EPS (TTM)28.20
Shares Outstanding941,741,400
10 Day Avg. Volume3,213,906
30 Day Avg. Volume3,283,388
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)36.37
Price to Sales (P/S)14.81
P/FCF Ratio107.56
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue15.02
Enterprise Value/Gross Profit17.99
Enterprise Value/Ebitda32.43
Forecast
1Y Price Target
$1,289.33Price Target Upside39.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)36.61
Revenue Forecast (FY)$84.88B
Bulls Say, Bears Say
Bulls Say
Sustained Revenue GrowthExceptionally strong, broad-based top-line momentum reflects durable demand for incretins and other franchises. A 56% Q1 gain and a guided FY uplift show structural volume and geographic expansion, supporting multi-quarter revenue visibility as products scale globally and fuel recurring revenue.
High Margins And Improving ProfitabilityVery high gross margins and a 50% non-GAAP performance margin indicate strong pricing power and manufacturing economics typical of patented biologics. This margin profile underpins durable cash flow generation and reinvestment capacity, supporting R&D and BD while enabling sustained operating leverage as scale grows.
Deep Pipeline And New ApprovalsApproval of Foundayo plus a large Phase III slate and targeted acquisitions create a durable engine to replenish revenues beyond current incretins. Diversified late-stage programs and BD broaden therapeutic reach, lowering single-product concentration risk and supporting medium-term growth and lifecycle sustainability.
Bears Say
Elevated LeverageMaterial leverage increases financial sensitivity to interest rates and compresses strategic flexibility. With debt near $43B and debt/equity elevated, major investments or slower growth could strain cash priorities; recent large debt issuance to fund deals further ties capital structure to execution outcomes.
Pricing Headwinds And Access VariabilityAnticipated multi-digit pricing pressure and payer access variability are structural risks that can erode realized revenue per unit. Given large exposure to U.S. payers and ongoing negotiations, durable reimbursement constraints could limit margin expansion and slow monetization of new indications over several quarters.
High Reliance On Self-pay ChannelsHeavy dependence on out-of-pocket and digital self-pay channels makes demand sensitive to affordability and coverage shifts. Employer or PBM coverage changes and patient cost sensitivity can durably reduce uptake velocity, complicating sustainable scale and exposing revenue to policy and payer decisions.
Eli Lilly & Co News
LLY FAQ
What was Eli Lilly And Company’s price range in the past 12 months?
Eli Lilly And Company lowest stock price was $623.78 and its highest was $1182.73 in the past 12 months.
What is Eli Lilly And Company’s market cap?
Eli Lilly And Company’s market cap is $1.06T.
When is Eli Lilly And Company’s upcoming earnings report date?
Eli Lilly And Company’s upcoming earnings report date is Aug 05, 2026 which is in 48 days.
How were Eli Lilly And Company’s earnings last quarter?
Eli Lilly And Company released its earnings results on Apr 30, 2026. The company reported $8.55 earnings per share for the quarter, beating the consensus estimate of $6.972 by $1.578.
Is Eli Lilly And Company overvalued?
According to Wall Street analysts Eli Lilly And Company’s price is currently Undervalued.
Does Eli Lilly And Company pay dividends?
Eli Lilly And Company pays a Quarterly dividend of $1.73 which represents an annual dividend yield of 0.58%. See more information on Eli Lilly And Company dividends here
What is Eli Lilly And Company’s EPS estimate?
Eli Lilly And Company’s EPS estimate is 8.81.
How many shares outstanding does Eli Lilly And Company have?
Eli Lilly And Company has 941,741,400 shares outstanding.
What happened to Eli Lilly And Company’s price movement after its last earnings report?
Eli Lilly And Company reported an EPS of $8.55 in its last earnings report, beating expectations of $6.972. Following the earnings report the stock price went up 9.797%.
Which hedge fund is a major shareholder of Eli Lilly And Company?
Currently, no hedge funds are holding shares in LLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eli Lilly & Co Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,289.33 (39.08% Upside)
$1,289.33 (39.08% Upside)
Blogger Sentiment
Bullish
LLY Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 140.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $15.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 8.8%
Last 30 Days ▲ 8.8%
News Sentiment
Very Bullish
Bullish news 91%
Bearish news 9%
Bearish news 9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.97%
12-Months-Change
Fundamentals
Return on Equity
101.30%
Trailing 12-Months
Asset Growth
30.41%
Trailing 12-Months
Company Description
Eli Lilly And Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
LLY Company Deck
LLY Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial picture: exceptional revenue and earnings growth, raised guidance, robust international momentum for incretins, successful clinical readouts (including cardiovascular safety for Foundayo), an ambitious pipeline with 42 active Phase III programs, and multiple strategic acquisitions to broaden capabilities. The principal concerns are meaningful pricing pressure (expected low-to-mid-teens headwind), increased marketing and R&D spend, access variability (Medicaid and payer coverage), early-stage uncertainty around Foundayo's ultimate contribution, and competitive/generic dynamics in some markets. On balance, the highlights materially outweigh the lowlights.View all LLY earnings summariesLLY Revenue Breakdown
35.23% Mounjaro
20.78% Zepbound
8.78% Verzenio
35.21% Other products
LLY Stock 12 Month Forecast
Average Price Target
$1,289.33
▲(39.08% Upside)
Technical Analysis
Ownership Overview
9.91% Insiders
22.76% Mutual Funds
26.77% Other Institutional Investors
21.13% Public Companies and Individual Investors